Recent Analysis Shows Rite Aid, Infosys, Morningstar, Western Digital, Hemispherx BioPharma, and Chanticleer Market Influences — Renewed Outlook, Key Drivers of Growth

16-04-2019

NEW YORK, April 16, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Rite Aid Corporation (NYSE:RAD), Infosys Limited (NYSE:INFY), Morningstar, Inc. (NASDAQ:MORN), Western Digital Corporation (NASDAQ:WDC), Hemispherx BioPharma, Inc. (NYSE:HEB), and Chanticleer Holdings, Inc. (NASDAQ:BURG), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

RAD DOWNLOAD: https://Capital-Review.com/register/?so=RAD
INFY DOWNLOAD: https://Capital-Review.com/register/?so=INFY
MORN DOWNLOAD: https://Capital-Review.com/register/?so=MORN
WDC DOWNLOAD: https://Capital-Review.com/register/?so=WDC
HEB DOWNLOAD: https://Capital-Review.com/register/?so=HEB
BURG DOWNLOAD: https://Capital-Review.com/register/?so=BURG

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Capital Review, available for free download at the links above, examine Rite Aid Corporation (NYSE:RAD), Infosys Limited (NYSE:INFY), Morningstar, Inc. (NASDAQ:MORN), Western Digital Corporation (NASDAQ:WDC), Hemispherx BioPharma, Inc. (NYSE:HEB), and Chanticleer Holdings, Inc. (NASDAQ:BURG) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

RITE AID CORPORATION (RAD) REPORT OVERVIEW

Rite Aid's Recent Financial Performance

For the three months ended February 28th, 2019 vs February 28th, 2018, Rite Aid reported revenue of $5,379.65MM vs $5,394.26MM (down 0.27%) and analysts estimated basic earnings per share -$0.26 vs $0.73. For the twelve months ended February 28th, 2019 vs February 28th, 2018, Rite Aid reported revenue of $21,639.56MM vs $21,528.97MM (up 0.51%) and analysts estimated basic earnings per share -$0.40 vs $0.90. Analysts expect earnings to be released on June 26th, 2019. The report will be for the fiscal period ending May 31st, 2019. The reported EPS for the same quarter last year was -$0.01.

To read the full Rite Aid Corporation (RAD) report, download it here: https://Capital-Review.com/register/?so=RAD

-----------------------------------------

INFOSYS LIMITED (INFY) REPORT OVERVIEW

Infosys' Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Infosys reported revenue of $2,987.00MM vs $2,755.00MM (up 8.42%) and analysts estimated basic earnings per share $0.12 vs $0.17 (down 29.41%). For the twelve months ended March 31st, 2018 vs March 31st, 2017, Infosys reported revenue of $10,939.00MM vs $10,208.00MM (up 7.16%) and analysts estimated basic earnings per share $0.55 vs $0.47 (up 17.02%). Analysts expect earnings to be released on July 12th, 2019. The report will be for the fiscal period ending June 30th, 2019. Reported EPS for the same quarter last year was $0.14. The estimated EPS forecast for the next fiscal year is $0.61 and is expected to report on April 10th, 2020.

To read the full Infosys Limited (INFY) report, download it here: https://Capital-Review.com/register/?so=INFY

-----------------------------------------

MORNINGSTAR, INC. (MORN) REPORT OVERVIEW

Morningstar's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Morningstar reported revenue of $262.70MM vs $243.10MM (up 8.06%) and analysts estimated basic earnings per share $1.00 vs $0.92 (up 8.70%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, Morningstar reported revenue of $1,019.90MM vs $911.70MM (up 11.87%) and analysts estimated basic earnings per share $4.30 vs $3.21 (up 33.96%). Analysts expect earnings to be released on April 24th, 2019. The report will be for the fiscal period ending March 31st, 2019.

To read the full Morningstar, Inc. (MORN) report, download it here: https://Capital-Review.com/register/?so=MORN

-----------------------------------------

WESTERN DIGITAL CORPORATION (WDC) REPORT OVERVIEW

Western Digital's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Western Digital reported revenue of $4,233.00MM vs $5,336.00MM (down 20.67%) and basic earnings per share -$1.68 vs -$2.78. For the twelve months ended June 30th, 2018 vs June 30th, 2017, Western Digital reported revenue of $20,647.00MM vs $19,093.00MM (up 8.14%) and analysts estimated basic earnings per share $2.27 vs $1.38 (up 64.49%). Analysts expect earnings to be released on April 29th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $3.36. The estimated EPS forecast for the next fiscal year is $4.04 and is expected to report on July 25th, 2019.

To read the full Western Digital Corporation (WDC) report, download it here: https://Capital-Review.com/register/?so=WDC

-----------------------------------------

HEMISPHERX BIOPHARMA, INC. (HEB) REPORT OVERVIEW

Hemispherx BioPharma's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Hemispherx BioPharma reported revenue of $0.24MM vs $0.05MM (up 380.00%) and analysts estimated basic earnings per share -$0.03 vs -$0.06. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Hemispherx BioPharma reported revenue of $0.37MM vs $0.44MM (down 16.02%) and analysts estimated basic earnings per share -$0.22 vs -$0.29. Analysts expect earnings to be released on May 15th, 2019. The report will be for the fiscal period ending March 31st, 2019.

To read the full Hemispherx BioPharma, Inc. (HEB) report, download it here: https://Capital-Review.com/register/?so=HEB

-----------------------------------------

CHANTICLEER HOLDINGS, INC. (BURG) REPORT OVERVIEW

Chanticleer's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Chanticleer reported revenue of $10.12MM vs $10.08MM (up 0.37%) and analysts estimated basic earnings per share -$0.58 vs -$0.43. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Chanticleer reported revenue of $40.61MM vs $41.43MM (down 1.98%) and analysts estimated basic earnings per share -$1.98 vs -$2.73. Analysts expect earnings to be released on May 13th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.30. The estimated EPS forecast for the next fiscal year is -$0.96 and is expected to report on April 6th, 2020.

To read the full Chanticleer Holdings, Inc. (BURG) report, download it here: https://Capital-Review.com/register/?so=BURG

-----------------------------------------

ABOUT CAPITAL REVIEW

Capital Review is a nationally recognized publisher of financial analysis, research reports, and exclusive market reporting. Institutional investors, registered brokers, professional traders, and personal investment advisers rely on Capital Review to quantify public company valuations, discover opportunity across asset classes, stay informed about market-moving events, and read exclusive analysis of important material developments. With 14 offices worldwide, Capital Review staffs and manages certified and registered financial professionals, including Chartered Financial Analyst® (CFA®) designation holders and FINRA® BrokerCheck® certified individuals with current and valid CRD® number designations, to enable continuous coverage of topics relevant to its regular active reader base.

REGISTERED MEMBER STATUS

Capital Review's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Capital Review's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Capital Review have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Capital Review's Compliance department by Phone, at +1 (410) 280-7496, or by E-mail at compliance@Capital-Review.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Capital Review, Capital Review members, and/or Capital Review affiliates are not responsible for any gains or losses that result from the opinions expressed. Capital Review makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Capital Review has not been compensated for the publication of this press release by any of the above mentioned companies. Capital Review is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Morena Zambada, Media Department
Office: +1 (410) 280-7496
E-mail: media@Capital-Review.com

© 2019 Capital Review. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Capital-Review.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

Latest news
Related news
Related shares
Western Digital Corporation
VOL 3,081,105
52.88 USD
1.39 / 2.70 %

Infosys Limited American Depos
VOL 1,668,539
11.55 USD
0.06 / 0.52 %

Rite Aid Corporation
VOL 374,936
7.190 USD
-0.60 / -7.70 %

Morningstar Inc
VOL 62,261
156.32 USD
1.84 / 1.19 %